SNY

Sanofi's stock trades above key moving averages as Dupixent and new drugs drive growth, while pipeline setbacks and vaccine weakness weigh.

On August 10, Trump signed Executive Order 14420. But I believe the pressure on Sanofi stock from Trump's Gold Standard Childhood Vaccine Recommendations will be temporary. Sanofi is trading at a significant discount, with a non-GAAP P/E ratio [FWD] of 9.2x, 53.2% below the sector median.

Sanofi is rated a Buy, with ~33.5% upside to €99.5 fair value (or $57 for SNY ADRs), resulting from averaging optimistic with pessimistic scenarios. Dupixent remains Sanofi's key growth driver, with a €25B 2030 sales target, but faces biosimilar risk post-2031 and a significant lawsuit threat. New pharma launches and pipeline assets are expected to offset legacy declines, targeting €10B in 2030 sales and with possible margin expansion toward 40%.

Sanofi's MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease Paris, August 4, 2026. Sanofi today announced that the European Commission (EC) has approved an extension of the indication for MenQuadfi (Meningococcal Group A, C, W and Y conjugate vaccine) to include infants from six weeks of age to help protect against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.

SNY beats on Q2 earnings and sales as Dupixent tops euro 5B in quarterly sales for the first time. The company also raises its 2026 outlook.

Sanofi NASDAQ: SNY raised its 2026 outlook after reporting double-digit second-quarter sales and earnings growth, driven by Dupixent, recently launched medicines and cost discipline. The company also increased its 2030 sales ambition for Dupixent to approximately €25 billion while outlining an ongoing review of its research pipeline and broader growth strategy.

The company now expects 2026 sales to grow by around 10% excluding currency changes, with business earnings per share rising slightly faster than sales.

Sanofi on Thursday raised its full-year sales forecast on the ​back of strong demand for blockbuster ‌asthma drug Dupixent, with investors focused on new CEO Belen Garijo's first address for her plans ​to revive the French company's drug development ​engine.

The drugmaker said efficacy and safety data didn't support further development of the drug, amlitelimab, for atopic dermatitis.

Sanofi today announced discontinuation of clinical development of amlitelimab, an OX40-ligand monoclonal antibody, in moderate-to-severe atopic dermatitis.